Moderna's official financial statements or press releases for 2025

Moderna Cuts 2025 Revenue Forecast to $1.5B-$2.5B, Plans $1B Cost Reduction Amid 20% Stock Drop

Jan 13, 2025, 12:28 PM

Moderna Inc. has revised its 2025 revenue forecast downwards to a range of $1.5 billion to $2.5 billion, a significant reduction from its previous projection of $2.5 billion to $3.5 billion. This adjustment comes in response to slower-than-expected demand for its Covid-19 and RSV vaccines. The company also reported 2024 product sales of between $3.0 billion and $3.1 billion, with an ending cash balance of approximately $9.5 billion. Moderna anticipates ending 2025 with a cash balance of about $6.0 billion. In an effort to manage costs, the company plans to reduce 2025 cash cost expenses by $1 billion, with an additional $0.5 billion in cost reductions targeted for 2026. Moderna is also focusing on its pipeline, anticipating milestones across 10 prioritized programs, including up to three potential approvals and six data readouts in 2025. The company's stock experienced a sharp decline, falling 20% in pre-market trading following the announcement.